Branddocs acquires and merges with TrustCloud – becomes the first global digital transactions choreographer
11.4.2023 12:30:00 EEST | Business Wire | Press release
Branddocs Inc, a prominent provider of secure digital transactions and video verification services, has announced today it is acquiring TrustCloud Inc, the world's first choreographing platform for secure digital transactions, in a move that strengthens its commitment to building trust and confidence in the digital economy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230411005217/en/
The Capabilities of the TrustCloud Choreography Platform (Graphic: Business Wire)
The newly merged company will trade as TrustCloud; combining former Branddocs’ large client base and its in-house network of fraud detection experts, AI/ML technologies, multi-orchestration capabilities and the widely acclaimed TrustCloud modular platform to deliver a globally compliant, frictionless and vendor-agnostic user journey. Clients include industry leaders such as JPMorgan Chase, Santander, BBVA, Willis Tower Watson, Direct Line and HDI, as well as government entities, healthcare providers and fast-growing Fintech companies, to name but a few.
“Knowing we can now offer one singular SaaS platform with one API and SLA across all our integrated vendors means our clients can now implement truly global and transformational orchestration solutions for every type of digital transaction – from eSignature to IAM and ID verification to the custody of digital assets in TrustCloud Vault. Our plug and play platform prevents the heartache of vendor lock-in, empowering clients with the freedom to choose any provider with per-transaction pricing. Any existing solution can be seamlessly integrated into TrustCloud’s vendor hub, which means zero interruption to our clients’ infrastructure and services,” states Branddocs’ CEO, Christoph Sauerwein.
As the world’s most certified Qualified Trust Service Provider (QTSP), TrustCloud effectively shields clients' global digital ecosystems, ensuring additional security and compliance at every level of transactional orchestration. Its unique choreographic ability allows for seamless management of high transaction volumes across various geographies while still maintaining an agile and adaptable approach.
“TrustCloud's unwavering commitment to building trust, coupled with cutting-edge technology and simplification of processes, enables businesses and consumers to engage in online transactions with greater ease and security. Due to our humanistic approach, by prioritising user control and visibility across the digital journey, we are seeing conversion rates significantly increase for our clients,” says Saioa Echebarria, CEO of TrustCloud.
About TrustCloud
TrustCloud is a secure digital transaction choreographer (SDTC) providing a range of services, including identity verification, authentication and authorization, encryption, digital signature verification, e-vaulting and e-archiving. These services are designed to protect the confidentiality, integrity, and availability of sensitive information, such as personal and financial data, throughout the entire digital transaction process. TrustCloud is also recognised as the most certified Qualified Trust Service Provider (QTSP) globally with certifications including ISO 27001, 17068, 22301, 27017, 27018, 27701, NIST 800-63 & 800-171, SOC2, HIPAA and eIDAS among others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005217/en/
Contact information
For further information visit Trustcloud.tech. For press enquiries email: press@trustcloud.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom